AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
作者:
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);苯磺酸盐类(Benzenesulfonates);癌, 肾细胞(Carcinoma, Renal Cell);双盲法(Double-Blind Method);酶联免疫吸附测定(Enzyme-Linked Immunosorbent Assay);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);烟酰胺(Niacinamide);苯脲化合物(Phenylurea Compounds);预后(Prognosis);吡啶类(Pyridines);重组融合蛋白质类(Recombinant Fusion Proteins);存活率(Survival Rate)
DOI
10.1002/cncr.27632
PMID
22692704
发布时间
2022-04-08
- 浏览124

Cancer
6152-61页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文